Evidence Healthcare Pharmaceuticals 
Complex Discovery
OCTOBER 19, 2024
Editor’s Note: Artificial intelligence (AI) is transforming the pharmaceutical industry, offering unprecedented opportunities to accelerate drug discovery, streamline clinical trials, and fortify intellectual property (IP) strategies.
IP Watchdog
JUNE 21, 2022
Court of Appeals for the Federal Circuit issued a precedential decision in Novartis Pharmaceuticals Corp. Accord Healthcare, Inc. Earlier today, the U.S. granting a petition for rehearing from appellant HEC Pharm Co.,
Complex Discovery
NOVEMBER 3, 2024
As October 2024 concluded, it continues to be evident that the eDiscovery, cybersecurity, and information governance sectors are undergoing significant transformations. As AI becomes a critical tool in pharmaceutical innovation, it also presents challenges around data security, governance, and legal accountability. Read the update.
Expert insights. Personalized for you.
111 
Let's personalize your content